Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash & Current Investments (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Cash & Current Investments for 10 consecutive years, with $421.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 30.98% to $421.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $421.0 million, a 30.98% decrease, with the full-year FY2025 number at $421.0 million, down 30.98% from a year prior.
  • Cash & Current Investments was $421.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $202.5 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $965.4 million in Q1 2021 to a low of $85.8 million in Q1 2023.
  • A 5-year average of $447.9 million and a median of $431.5 million in 2023 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: crashed 85.67% in 2023, then surged 648.41% in 2024.
  • Ultragenyx Pharmaceutical's Cash & Current Investments stood at $740.2 million in 2021, then increased by 1.02% to $747.8 million in 2022, then fell by 22.75% to $577.6 million in 2023, then rose by 5.6% to $610.0 million in 2024, then plummeted by 30.98% to $421.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Cash & Current Investments are $421.0 million (Q4 2025), $202.5 million (Q3 2025), and $176.3 million (Q2 2025).